Category: Ascendis Pharma shares surge 42% as competitor Versartis plummets 85% on failed trial

Ascendis Pharma shares surge 42% as competitor Versartis plummets 85% on failed trial

  1. Ascendis Pharma shares surge 42% as competitor Versartis plummets 85% on failed trial  MarketWatch
  2. This Biotech Is Ascending To Record Highs After Rival’s Failure  Investor’s Business Daily
  3. Analysts: Game On for ASND as Rival Drug Stock VSAR Spirals Lower  Schaeffers Research (blog)
  4. Full coverage

from Business – Google News http://www.marketwatch.com/story/ascendis-pharma-shares-surge-42-as-competitor-versartis-plummets-85-on-failed-trial-2017-09-22

Advertisements